08:20 AM EST, 01/16/2025 (MT Newswires) -- BioVaxys Technology ( BVAXF ) on Thursday said it is developing its DPX platform to be the "carrier of choice" for mRNA vaccines.

Data from proof-of-concept studies of DPX-mRNA formulations conducted in collaboration with RNA technology company Etherna and PCI Biotech demonstrate that DPX provides enhanced in vitro and in vivo stability of packaged mRNA, BioVaxys ( BVAXF ) said.

The DPX platform facilitates antigen delivery to regional lymph nodes and has been demonstrated to induce "robust and durable" T cell and B cell responses in pre-clinical and clinical studies for both cancer and infectious disease, a statement noted.

"The DPX platform is essentially a 'pipeline from a product' and will play a significant commercial role for the company as an enabling technology for delivering nucleic acids and other antigens," said President and Chief Operating Officer Kenneth Kovan. "DPX is ideal for mRNA delivery, as it remains localized and does not spill out from the injection site and has superior stability than LNPs [lipid nanoparticles]."